Esperion Therapeutics Stock Price (NASDAQ:ESPR)

Add to My Stocks
$48.8 $2.6 (5.63%) ESPR stock closing price Jul 20, 2017 (Closing)
Prev Close* : $46.20
Market Cap:
Day Low: $46.1
52 Week Low: $9.40
Open: $46.53
Volume: 783676
Day High: $50.05
52 Week High: $50.52

Latest Stock Market News

Latest Articles

Esperion Therapeutics News - From Partners

ESPR Stockcharts

View ESPR PE ratio, PS ratio stocks charts and compare with peers.
ESPR Chart
Note: Compare Esperion Therapeutics stock price history with the index and industry peers.

ESPR Industry Peers

Company Price Change (%)
Furiex Pharmaceuticals (FURX)104.770 (0%)
Xencor (XNCR)230.62 (2.62%)
Aegerion Pharma (AEGR)1.970.1 (5.35%)
Gemphire Therap (GEMP)16.70.65 (3.75%)
Regeneron Pharma (REGN)521.1314.34 (2.83%)
Abbvie (ABBV)74.011.24 (1.7%)
Merck (MRK)62.940.32 (0.51%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Tetraphase Pharmaceuticals (TTPH)7.870.46 (6.21%)
Esperion Therapeutics (ESPR)48.82.6 (5.63%)
PTC Therapeutics (PTCT)20.340.91 (4.68%)
GlycoMimetics (GLYC)11.830.52 (4.6%)
MediWound (MDWD)7.250.3 (4.32%)
Catalyst Pharma (CPRX)3.050.12 (4.1%)
Tesaro Inc (TSRO)129.025 (4.03%)
Top gainers from Medical-Drugs industry
* As of Jul 20, 2017
CompanyPriceChange (%)
Adamis Pharma (ADMP)4.650.45 (8.82%)
Ironwood Pharma (IRWD)171.55 (8.36%)
Ignyta (RXDX)8.80.4 (4.35%)
Xencor (XNCR)230.62 (2.62%)
Achaogen (AKAO)22.310.47 (2.06%)
Enanta Pharma (ENTA)36.420.6 (1.62%)
Shire (SHPG)160.222.57 (1.58%)
Top losers from Medical-Drugs industry
* As of Jul 20, 2017

Esperion Therapeutics Inc Stock News - Partner Headlines

Esperion Therapeutics Financial Statements

income statement20162015201420132012
Net Sales Or Revenues-----
Net Income-74.97M-49.78M-36.37M-26.08M-11.65M
Total Operating Expense76.14M50.03M36.22M22.75M10.19M
view Esperion Therapeutics Inc income statement
balance sheet20162015201420132012
Total Assets245.21M295.57M143.34M78.29M7.31M
Total Liabilities16.61M8.31M9.79M4.2M24.7M
Shareholders Equity228.6M287.25M133.55M74.09M-17.38M
view Esperion Therapeutics Inc balance sheet
cash flow statement20162015201420132012
Net Increase (Decrease) In Assets Liabilities9.98M-2.08M0.25M3.22M-0.84M
Net Cash From (Used By) Operating Activities-47.73M-38.15M-32.02M-18.11M-10.8M
Increase (Decrease) In Prop Plant And Equipment-0.09M-0.3M-0.86M0.16M-
view Esperion Therapeutics Inc cashflow statement

Esperion Therapeutics Stock Message Board

arnulacroix22 on Esperion Therapeutics stock analysis ($44.79)
watch Esperion Therapeutics, Inc. (Nasdaq:ESPR) Stock @current levels. The FDA has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. The action by the FDA will now allow the company to conduct clinical trials exceeding six months in duration Check this out

As of last trading day, Esperion Therapeutics stock price was 46.2. The total market value as denoted by 1.07B for Esperion Therapeutics, is the market value of the company's outstanding shares. Esperion Therapeutics valuation can be guaged using various valuation metrics like the price to earnings ratio.

Demand for a stock decides its stock market price. For example, if more investors want to buy ESPR stock than sell it, then Esperion Therapeutics stock price goes up. Conversely, if more investors wanted to sell ESPR stock than buy it, there would be greater supply than demand, and the stock price would fall. 384372 shares were traded with a closing stock price of 46.2 as of 19 Jul, 2017, as can be seen from Esperion Therapeutics stock quote. One can view Esperion Therapeutics stock chart to follow the stock price trend. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. Esperion Therapeutics stock price history, gives the entire historical data for ESPR stock.